comparemela.com
Home
Live Updates
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024 : comparemela.com
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024
/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities...
Related Keywords
China ,
Shanghai ,
Guangzhou ,
Guangdong ,
Hangzhou ,
Zhejiang ,
Princeton ,
Massachusetts ,
United States ,
Boston ,
Beijing ,
Suzhou ,
Jiangsu ,
Los Angeles ,
Product Development Center ,
Prnewswire Transcenta Holding Limited ,
Transcenta Immune Tolerance Breaking Technology ,
Clinical Development Centers In Princeton ,
Group Headquarters ,
Translational Research Center ,
Holding Limited ,
Clinical Oncology Volume ,
Immune Tolerance Breaking Technology ,
Orphan Drug Designation ,
Manufacturing Facility ,
Clinical Development Centers ,
External Partnering Center ,
Suzhou Industrial ,
comparemela.com © 2020. All Rights Reserved.